Express Pharma

APRIL 3, 2023

The diagnosed prevalent cases of gastric, breast, and bladder cancers in China are expected to increase at a compound annual growth rate (CAGR) of 2.6 per cent, and 3 per cent, respectively, between 2022 and 2028. These companies have active research and development collaborations with various local players worldwide.

Chemotherapy 98

Chemotherapy Compounding Drug Development 98

Syner-G

SEPTEMBER 15, 2023

This shift from a linear to a network approach enhances the potential for one drug to target multiple sites. Structure-based drug design has evolved, facilitating the exploration of novel chemical probes and lead compound potency, and molecular docking utilizes target structures to predict interactions and offers simplicity and speed.

Drug Development 59

Drug Development Documentation Process Improvement Compounding 59

pharmaphorum

AUGUST 2, 2022

The potential for ADCs to combine the best of both mAbs and small molecule drugs means that there has been high interest in developing a successful compound since the first successful clinical trial in 1983. At present, there are 12 approved treatments and the development work being done to bring more through is only increasing.

Compounding 98

Compounding Drug Development 98

Express Pharma

SEPTEMBER 24, 2023

The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2 billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR). This ascent is propelled by favorable regulatory developments, including pioneering clinical trial guidelines from the FDA. billion in sales in 2029.

Drug Development 52

Drug Development Compounding 52

Pharmaceutical Technology

AUGUST 12, 2022

By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. Notable Phase II drugs include Allogene Therapuetics’s ALLO-501A, Autolus Therapeutics’s obecabtagene autoleucel, CASI Pharmaceuticals’s CNCT-19, Precision Biosciences’s PBCAR-0191, and Mustang Bio’s MB-106.

Immunization 52

Immunization Immunity Chemotherapy Compounding 52

Pharmaceutical Technology

FEBRUARY 13, 2023

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas.

Dosage 59

Dosage Chemotherapy Compounding Immunization 59

PharmaTech

JUNE 12, 2025

By combining assets, both companies aim to streamline mRNA drug development pipelines and manufacturing workflows, potentially reducing timelines for delivering clinical-stage therapies to patients. This news comes just 10 days after BioNTech announced a global co-development and co-commercialization agreement valued at up to $11.1

Dosage 52

Dosage Drug Development Vaccines Packaging 52